Results 1 to 10 of about 2,560,648 (253)

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours [PDF]

The Journal of Pathology: Clinical Research, 2023
Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 (NTRK2) gene, and its abnormal activation caused ...
Yuehua Li, Chengjiang Wei, Wei Wang, Qingfeng Li, Zhi‐Chao Wang   +4 more
doaj   +4 more sources

A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma [PDF]

PeerJ, 2019
Neurotrophic receptor tyrosine kinase 2 (NTRK2) is a member of the tropomyosin receptor kinase family associated with the tumor development. However, the detailed function of NTRK2 in lung cancer, especially in lung adenocarcinoma (LUAD), is still not ...
Xiang Wang, Zhijie Xu, Xi Chen, Xinxin Ren, Jie Wei, Shuyi Zhou, Xue Yang, Shuangshuang Zeng, Long Qian, Geting Wu, Zhicheng Gong, Yuanliang Yan   +11 more
doaj   +6 more sources

Downstream of tyrosine kinase/docking protein 6, as a novel substrate of tropomyosin-related kinase C receptor, is involved in neurotrophin 3-mediated neurite outgrowth in mouse cortex neurons [PDF]

BMC Biology, 2010
Background The downstream of tyrosine kinase/docking protein (Dok) adaptor protein family has seven members, Dok1 to Dok7, that act as substrates of multiple receptor tyrosine kinase and non-receptor tyrosine kinase.
Yuan Jian, Gong Yan, Yin Bin, Shi Lei, You Yuan, Li Wei, Peng Xiao   +6 more
doaj   +2 more sources

Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies [PDF]

Frontiers in Chemistry, 2023
Tropomyosin-receptor kinase A (TrkA) is the primary isoform among the tropomyosin-receptor kinases that have been associated with human cancer development, contributing to approximately 7.4% of all cancer cases.
Rua M. Mukhtar, Nihal Abdelmoniem, Hisham A. Elrufaie, Alaa Edris, Hiba Ghaboosh, Mohanad A. Mahgoub, Elrashied A. E. Garelnabi, Wadah Osman, Wadah Osman, Asmaa E. Sherif, Asmaa E. Sherif, Ahmed Ashour, Ahmed Ashour, Kholoud F. Ghazawi, Waad A. Samman, Aisha A. Alhaddad, Rawan Bafail, Sabrin R. M. Ibrahim, Sabrin R. M. Ibrahim, Gamal A. Mohamed, Abdulrahim A. Alzain   +20 more
doaj   +2 more sources

Identification and characterization of the Cucurbitacins, a novel class of small-molecule inhibitors of Tropomyosin receptor kinase a [PDF]

BMC Complementary and Alternative Medicine, 2019
Background NGF-TrkA is well known to play a key role in propagating and sustaining pruritogenic signals, which form the pathology of chronic pruritus. Inhibition of NGF-TrkA is a known strategy for the treatment of pruritus.
Yueling Zhong, Hong Xu, Yi Zhong, Xuemiao Zhang, Ting Zeng, Limei Li, Gaojie Xu, Minhui Li, Jin Liu, Tai Yang   +9 more
doaj   +6 more sources

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. [PDF]

Cancer, 2023
AbstractBackgroundLarotrectinib, a first‐in‐class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions. This subset analysis focuses on the efficacy and safety of larotrectinib in an expanded cohort of adult patients with TRK fusion
Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcón SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW.   +23 more
europepmc   +5 more sources

Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs [PDF]

Journal of Medicinal Chemistry, 2020
Tropomyosin receptor kinases (TRKs) are promising cancer therapeutic targets. Chen ( J. Med. Chem. 2020, DOI: 10.1021/acs.jmedchem.0c01342) report the discovery of CG416 and CG428 as two potent small-molecule proteolysis-targeting chimera (PROTAC) degraders selective for TRKA over TRKB and TRKC.
Weiguo Xiang, Shaomeng Wang
openalex   +4 more sources

Regulation of Eosinophil Recruitment and Allergic Airway Inflammation by Tropomyosin Receptor Kinase A. [PDF]

J Immunol, 2020
Abstract Eosinophilia is a hallmark of allergic airway inflammation (AAI). Identifying key molecules and specific signaling pathways that regulate eosinophilic inflammation is critical for development of novel therapeutics. Tropomycin receptor kinase A (TrkA) is the high-affinity receptor for nerve growth factor.
Dileepan M, Ge XN, Bastan I, Greenberg YG, Liang Y, Sriramarao P, Rao SP, Rao SP.   +7 more
europepmc   +5 more sources

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. [PDF]

JCO Precis Oncol, 2022
PURPOSELarotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy and safety of larotrectinib in patients with TRK fusion–positive lung cancers.MATERIALS AND METHODSData ...
Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ.   +15 more
europepmc   +6 more sources

Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway [PDF]

Cancer Medicine
Introduction A neurotrophic tropomyosin receptor kinase (NTRK)‐tyrosine kinase inhibitor (TKI) has shown dramatic efficacy against malignant tumors harboring an NTRK fusion gene.
Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike   +12 more
doaj   +2 more sources